Our team has continued working on autoimmune diseases and autoinflammatory disorders. Studies on the role of disturbances among immune cells, cytokines and autoantibodies and their relationship with recurrent pregnancy loss and inflammatory placental-related disorders are ongoing. Animal models were included in this research. The relationship between myositis and systemic sclerosis and cancer, as well as different autoantibody profiles, were analysed. Recent reported autoimmune diseases in oncologic patients treated with check point inhibitors also focused our interest. Gene-wide genetic and molecular signatures in systemic vasculitis, Sjögren syndrome and systemic sclerosis to find relationship with clinical subsets were studied. We described a new risk haplotype for autoimmune/granulomatous disorders in patients with bioimplants. Our latest research focuses on the study of immune mechanisms involved in thrombosis in COVID-19 in patients with and without antiphospholipid antibodies.

Group Leader
Jaume Alijotas Reig

Principal Investigator (PI)
Francesc Miró Mur, Albert Selva O’Callaghan, Carmen Pilar Simeón Aznar, Roser Solans Laqué, Josep Pardos Gea, Moisés Labrador Horrillo, Segundo Buján Rivas, Mar Guilarte Clavero, Victòria Cardona Dahl

Anna Sala Cunill, Alfredo Guillén del Castillo, Olga Luengo Sánchez, Fernando Martínez Valle, Jaume Mestre Torres, Enrique Esteve Valverde

PhD Students
Ariadna Anunciación Llunell, Joana Marques Soares

Lab Technicians
Laura Donaire, Daniel Granados Pino










Pardos-Gea J, Marques-Soares JR, Bujan S, Ordi-Ros J, Alijotas-Reig J
Persistent thrombocytopenia predicts poor long-term survival in patients with antiphospholipid syndrome: a 38-year follow-up study
Rheumatology (Oxford). 2022 Mar 2;61(3):1053-1061
DOI: doi: 10.1093/rheumatology/keab475
IF: 7.046

Mestre-Torres J, Martinez-Valle F, Gabaldon A, Simo-Perdigo M, Salcedo-Allende MT, Navales-Mateu I, Solans-Laque R
Are Temporal Artery Biopsy Findings Related to PET/CT Findings in Giant Cell Arteritis?
Clin Nucl Med. 2022 May 1;47(5):387-393
DOI: doi: 10.1097/RLU.0000000000004097
IF: 10.782

Carbonell C, Marcos M, Guillen-Del-Castillo, Rubio-Rivas M, Argibay A, Marin-Ballve A, Rodriguez-Pinto I, Balda-Masmiquel M, Callejas-Moraga E, Colunga D, Saez-Comet L, Gonzalez-Echavarri C, Ortego-Centeno N, Mari-Alfonso B, Vargas-Hitos JA, Todoli-Parra JA, Trapiella L, Herranz-Marin MT, Freire M, Castro-Salomo A, Perales-Fraile I, Madronero-Vuelta AB, Sanchez-Garcia ME, Ruiz-Munoz M, Gonzalez-Garcia A, Sanchez-Redondo J, de-la-Red-Bellvis G, Fernandez-Luque A, Muela-Molinero A, Lledo GM, Tolosa-Vilella C, Fonollosa-Pla V, Chamorro AJ, Simeon-Aznar CP
Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE)
Autoimmun Rev. 2022 Oct;21(10):103167
DOI: doi: 10.1016/j.autrev.2022.103167
IF: 17.39

Gimenez-Arnau A, Bartra J, Ferrer M, Jauregui I, Borbujo J, Figueras I, Munoz-Bellido FJ, Pedraz J, Serra-Baldrich E, Tejedor-Alonso MA, Velasco M, Terradas P, Labrador MA
Specialized Therapeutic Approach to Chronic Urticaria Patient’s Refractory to H1-Antihistamines Improves the Burden of the Disease. The Spanish AWARE Experience
J Investig Allergol Clin Immunol. 2022 Jun 20;32(3):191-199
DOI: doi: 10.18176/jiaci.0661
IF: 8.185

Anunciacion-Llunell , Munoz C, Roggenbuck D, Frasca S, Pardos-Gea J, Esteve-Valverde E, Alijotas-Reig J, Miro-Mur F
Differences in Antiphospholipid Antibody Profile between Patients with Obstetric and Thrombotic Antiphospholipid Syndrome
Int J Mol Sci. 2022 Oct 24;23(21). pii: ijms232112819
DOI: doi: 10.3390/ijms232112819
IF: 6.208

Design of an integrative patient stratification approach for the systemic sclerosis management
Principal Investigator: Carmen Pilar Simeón Aznar
Agency: Fundació La Marató de TV3
Funding: 72,250 €
Period: 2021-ongoing

Infiltrado Tumoral Linfocitario (TILs) y dermatomiositis asociada a cáncer
Principal Investigator: Albert Selva O’Callaghan
Agency: Instituto de Salud Carlos III
Funding: 133,000 €
Period: 2019-2022

Tratorns autoimmunes i al·loimmunes i la seva relació amb trastorns reproductius
Principal Investigator: Jaume Alijotas-Reig
Agency: Fundació Ona Futura / Gravida
Funding: 135,000 €
Period: 2019 –ongoing

Combination of immunosuppressors or immunomodulatory drugs in patients with severe acute infection caused by SARS-CoV-2: cellular and immunological basis
Principal Investigator: Jaume Alijotas-Reig
Agency: Ayudas a la investigación médica SEMCC 2020
Funding: 40,000 €
Period: 2020-2022

Identificación de biomarcadores celulares y moleculares en angioedema idiopático y hereditario para su diferenciación en fenotipos y endotipos
Principal Investigator: Mar Guilarte Clavero
Agency: Instituto de Salud Carlos III
Funding: 84,700 €
Period: 2021 - ongoing